Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yu Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5214-3183; OpenAlex author ID A5100602825. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1001↗
  2. Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. Co-author DOI 10.1016/j.cmet.2025.07.008↗
  3. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04742-y↗
  4. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant … Co-author DOI 10.1002/cam4.4698↗
  5. Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER-based analysis of 15,836 cases. First author DOI 10.1002/cam4.4147↗
  6. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis. First author DOI 10.1007/s00464-020-07791-2↗
  7. Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients. First author DOI 10.1186/s12885-021-09056-0↗
  8. Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective s… Last author DOI 10.7717/peerj.8811↗
  9. Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEE… Co-author DOI 10.3389/fonc.2019.01386↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 8 shared papers, 2019–2026 · strength 1.31
  2. Ningzhen Fu · 6 shared papers, 2019–2023 · strength 0.88
  3. Xiaxing Deng · 6 shared papers, 2019–2023 · strength 0.88
  4. Kai Qin · 3 shared papers, 2021–2023 · strength 0.50
  5. Jiabin Jin · 3 shared papers, 2021–2023 · strength 0.47
  6. Yuanchi Weng · 2 shared papers, 2021 · strength 0.29
  7. Siyi Zou · 2 shared papers, 2019–2025 · strength 0.29
  8. Hao Chen · 2 shared papers, 2019–2021 · strength 0.25
  9. Berina Šabanović · 1 shared paper, 2026 · strength 0.24
  10. Miriam Roberto · 1 shared paper, 2026 · strength 0.24
  11. Chenlei Wen · 1 shared paper, 2026 · strength 0.24
  12. Jingwei Li · 1 shared paper, 2026 · strength 0.24
  13. Yuntao YANG · 1 shared paper, 2026 · strength 0.24
  14. Christopher Heeschen · 1 shared paper, 2026 · strength 0.24
  15. Jiayu Lin · 1 shared paper, 2025 · strength 0.20
  16. Yihao Liu · 1 shared paper, 2025 · strength 0.20
  17. Yang Liu · 1 shared paper, 2025 · strength 0.20
  18. Pengyi Liu · 1 shared paper, 2025 · strength 0.20
  19. Jun Wang · 1 shared paper, 2023 · strength 0.17
  20. Yuchen Ji · 1 shared paper, 2023 · strength 0.17
  21. Yiran Zhou · 1 shared paper, 2023 · strength 0.17
  22. Dongfeng Cheng · 1 shared paper, 2023 · strength 0.17
  23. Chenghong Peng · 1 shared paper, 2021 · strength 0.13
  24. Zhen Huo · 1 shared paper, 2021 · strength 0.13
  25. Ankang Wang · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.